Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas.
Journal
Laboratory investigation; a journal of technical methods and pathology
ISSN: 1530-0307
Titre abrégé: Lab Invest
Pays: United States
ID NLM: 0376617
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
22
07
2019
accepted:
31
12
2019
revised:
31
12
2019
pubmed:
2
2
2020
medline:
21
10
2020
entrez:
2
2
2020
Statut:
ppublish
Résumé
Intraductal tubulopapillary neoplasm (ITPN) is a distinct precancerous lesion in the pancreas with unique clinical and molecular features. Although in vitro studies in two-dimensional culture have led to numerous important insights in pancreatic cancer, such models are currently lacking for precancerous lesions. In this study, we report the generation and characterization of a cell line from a human pancreatic ITPN. Neoplastic cells were initially cultured in a three-dimensional organoid system, followed by transfer to two-dimensional culture. RNA sequencing revealed a gene expression profile consistent with pancreatic ductal origin, and whole genome sequencing identified many somatic mutations (including in genes involved in DNA repair and Wnt signaling) and structural rearrangements. In vitro characterization of the tumorigenic potential demonstrated a phenotype between that of normal pancreatic ductal cells and cancer cell lines. This cell line represents a valuable resource for interrogation of unique ITPN biology, as well as precancerous pancreatic lesions more generally.
Identifiants
pubmed: 32005909
doi: 10.1038/s41374-020-0372-0
pii: S0023-6837(22)00453-6
pmc: PMC7316603
mid: NIHMS1591268
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1013Subventions
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA190889
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK107781
Pays : United States
Références
Basturk O, Adsay V, Askan G, Dhall D, Zamboni G, Shimizu M, et al. Intraductal tubulopapillary neoplasm of the pancreas: a clinicopathologic and immunohistochemical analysis of 33 cases. Am J Surg Pathol. 2017;41:313–25.
doi: 10.1097/PAS.0000000000000782
Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, et al. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2009;33:1164–72.
doi: 10.1097/PAS.0b013e3181a162e5
Adsay NVF, Furukawa T, Hruban RH, Klimstra DS, Kloppel G, Offerhaus GJA, et al. WHO classification of tumours of the digestive system, In: Bosman FTJ, Lakhani SR, Ohgaki H, editors. WHO classification of tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
Shahinian HK, Sciadini MF, Springer DJ, Reynolds VH, Lennington WJ. Tubular adenoma of the main pancreatic duct. Arch Surg. 1992;127:1254–5.
doi: 10.1001/archsurg.1992.01420100120022
Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, et al. A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol. 2015;39:1730–41.
doi: 10.1097/PAS.0000000000000533
Date K, Okabayashi T, Shima Y, Iwata J, Sumiyoshi T, Kozuki A, et al. Clinicopathological features and surgical outcomes of intraductal tubulopapillary neoplasm of the pancreas: a systematic review. Langenbecks Arch Surg. 2016;401:439–47.
doi: 10.1007/s00423-016-1391-6
Basturk O, Berger MF, Yamaguchi H, Adsay V, Askan G, Bhanot UK, et al. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Mod Pathol. 2017;30:1760–72.
doi: 10.1038/modpathol.2017.60
Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol. 2014;233:217–27.
doi: 10.1002/path.4344
Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000;157:1623–31.
doi: 10.1016/S0002-9440(10)64800-6
Kamiyama H, Kamiyama M, Hong SM, Karikari CA, Lin MT, Borges MW, et al. In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Lab Invest. 2010;90:665–73.
doi: 10.1038/labinvest.2010.51
Heller A, Angelova AL, Bauer S, Grekova SP, Aprahamian M, Rommelaere J, et al. Establishment and characterization of a novel cell line, ASAN-PaCa, derived from human adenocarcinoma arising in intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2016;45:1452–60.
doi: 10.1097/MPA.0000000000000673
Fritz S, Fernandez-del Castillo C, Iafrate AJ, Mino-Kenudson M, Neyhard N, LaFemina J, et al. Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanisms. Pancreas. 2010;39:308–14.
doi: 10.1097/MPA.0b013e3181bd5c10
Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am. 1998;4:194–203.
pubmed: 9612602
Zhao Z, Bauer N, Aleksandrowicz E, Yin L, Gladkich J, Gross W, et al. Intraductal papillary mucinous neoplasm of the pancreas rapidly xenografts in chicken eggs and predicts aggressiveness. Int J Cancer. 2018;142:1440–52.
doi: 10.1002/ijc.31160
Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018;22:454–67.e6.
doi: 10.1016/j.stem.2017.12.009
Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21:1364–71.
doi: 10.1038/nm.3973
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324–38.
doi: 10.1016/j.cell.2014.12.021
Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJ, van de Wetering M, et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 2013;32:2708–21.
doi: 10.1038/emboj.2013.204
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.
doi: 10.1038/nature07935
Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741–7.
doi: 10.1002/ijc.2910150505
Dixon JR, Xu J, Dileep V, Zhan Y, Song F, Le VT, et al. Integrative detection and analysis of structural variation in cancer genomes. Nat Genet. 2018;50:1388–98.
doi: 10.1038/s41588-018-0195-8
The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185–203.e13.
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
doi: 10.1038/nprot.2006.339
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.
doi: 10.1038/nature12477
Fu Y, Liu Z, Lou S, Bedford J, Mu XJ, Yip KY, et al. FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biol. 2014;15:480.
doi: 10.1186/s13059-014-0480-5
Hall DM, Brooks SA. In vitro invasion assay using matrigel: a reconstituted basement membrane preparation. Methods Mol Biol. 2014;1070:1–11.
doi: 10.1007/978-1-4614-8244-4_1
Schatoff EM, Goswami S, Zafra MP, Foronda M, Shusterman M, Leach BI, et al. Distinct colorectal cancer-associated APC mutations dictate response to tankyrase inhibition. Cancer Discov. 2019;9:1358–71.
doi: 10.1158/2159-8290.CD-19-0289
Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, et al. APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer. Mol Cancer Ther. 2017;16:752–62.
doi: 10.1158/1535-7163.MCT-16-0578
Yang X, Ndawula C Jr., Zhou H, Gong X, Jin J. JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib. Oncol Lett. 2015;9:757–61.
doi: 10.3892/ol.2014.2762
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.
doi: 10.1038/nature03443
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.
doi: 10.1038/nature03445
Soule HD, Maloney TM, Wolman SR, Peterson WD Jr., Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50:6075–86.
pubmed: 1975513
pmcid: 1975513
Matsui Y, Tsuchida Y, Keng PC. Effects of p53 mutations on cellular sensitivity to ionizing radiation. Am J Clin Oncol. 2001;24:486–90.
doi: 10.1097/00000421-200110000-00014
Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Slater JM, et al. Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation. Int J Radiat Oncol Biol Phys. 2008;72:909–17.
doi: 10.1016/j.ijrobp.2008.06.1928
The Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378–84.
Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
doi: 10.1038/nature14169